Clinical Trial

A Randomized, Open-label Study Comparing the Bria IMT Regimen in Combination with Check Point Inhibitor vs Physician’s Choice in Metastatic Breast Cancer (BRIA-ABC)

MOA: A Randomized, Open-label Study Comparing the Bria IMT Regimen in Combination with Check Point Inhibitor vs Physician’s Choice in Metastatic Breast Cancer (BRIA-ABC)

Key Eligibility:

• MBC that have failed prior tx and have no meaningful alternative tx available
  • HER2+: ≥3 prior tx with ≥2 anti-HER2 and ≥1 chemotherapy regiment
  • ER+/PR+: refractory to hormonal tx (PD on ≥2 agents, in 2 separate lines)
  • TNBC: must have exhausted all curative intent tx including ≥2 prior chemo (neo and/or adjuvant settings)
  • Known germline/genomic actionable targets: must have had all tumor directed indicated tx
  • HER2-low: ≥HER2-targeted agent approved HER2-low in addition to any HR tx or germline/genomic actionable targets tx
  • HER2-negative: refractory to HR tx (if indicated) and had ≥2 prior chemotherapy
  • New or progressive BC metastatic to the brain are eligible if clinically stable, does not require steroid or had it discontinued ≥2 weeks prior to the first dose, and ≥3 weeks since surgical debulking before first dose
  • ECOG: 0-2